Contact Dermatitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Contact Dermatitis can occur with symptoms that include red rash or bumps, dry, cracked, red patches, which may resemble a burn, and pain or tenderness. The treatment of Contact Dermatitis includes oral corticosteroids and antihistamines to relieve intense itching.
The Contact Dermatitis pipeline market report provides a comprehensive overview of the therapeutics under development for Contact Dermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Contact Dermatitis and features dormant and discontinued projects.
Contact Dermatitis Pipeline Drugs Market by Key Targets
In the Contact Dermatitis pipeline drugs market, the key targets are Glucocorticoid Receptor, Phospholipase A2, Sialic Acid Binding Ig Like Lectin 6, and Toll Like Receptor 4.
For more target insights, download a free report sample
Key MoA in the Contact Dermatitis Pipeline Drugs Market
The key mechanisms of action in the Contact Dermatitis pipeline drugs market are Glucocorticoid Receptor Agonist, Phospholipase A2 Inhibitor, Sialic Acid Binding Ig Like Lectin 6 Inhibitor, and Toll Like Receptor 4 Antagonist.
To get more insights on key MoA, download a free sample report
Contact Dermatitis Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Contact Dermatitis pipeline drug market are topical, cutaneous, intramuscular, intravenous, intravenous drip, and nasal. Topical has the maximum number of pipeline products.
Contact Dermatitis Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Contact Dermatitis Pipeline Drugs Market
The key molecule types in the Contact Dermatitis pipeline drugs market are small molecule, biologic, monoclonal antibody, and live attenuated vaccine. Small molecule has the maximum number of pipeline products.
Contact Dermatitis Pipeline Drugs Market, by Molecule Types
To get more insights on key molecule types, download a free sample report
Major Companies in the Contact Dermatitis Pipeline Drugs Market
Some of the major companies in the Contact Dermatitis pipeline drugs market are Edesa Biotech Inc, Allakos Inc, Aposcience AG, Hapten Sciences Inc, ILiAD Biotechnologies LLC, NextPhase Therapeutics, and Signum Dermalogix Inc.
Contact Dermatitis Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Contact Dermatitis Pipeline Drugs Market Overview
Key Targets | Glucocorticoid Receptor, Phospholipase A2, Sialic Acid Binding Ig Like Lectin 6, and Toll Like Receptor 4 |
Key Mechanisms of Action | Glucocorticoid Receptor Agonist, Phospholipase A2 Inhibitor, Sialic Acid Binding Ig Like Lectin 6 Inhibitor, and Toll Like Receptor 4 Antagonist |
Key Routes of Administration | Topical, Cutaneous, Intramuscular, Intravenous, Intravenous Drip, and Nasal |
Key Molecule Types | Small Molecule, Biologic, Monoclonal Antibody, and Live Attenuated Vaccine |
Major Companies | Edesa Biotech Inc, Allakos Inc, Aposcience AG, Hapten Sciences Inc, ILiAD Biotechnologies LLC, NextPhase Therapeutics, and Signum Dermalogix Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Contact Dermatitis
- The pipeline guide reviews pipeline therapeutics for Contact Dermatitis by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Contact Dermatitis therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Contact Dermatitis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Contact Dermatitis
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Contact Dermatitis
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Contact Dermatitis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Aposcience AG
Edesa Biotech Inc
Hapten Sciences Inc
ILiAD Biotechnologies LLC
NextPhase Therapeutics
Signum Dermalogix Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Contact Dermatitis pipeline drug market?
In the Contact Dermatitis pipeline drugs market the key targets are Glucocorticoid Receptor, Phospholipase A2, Sialic Acid Binding Ig Like Lectin 6, and Toll Like Receptor 4.
-
What are the key mechanisms of action in the Contact Dermatitis pipeline drugs market?
In the Contact Dermatitis pipeline drugs market the key mechanisms of action are Glucocorticoid Receptor Agonist, Phospholipase A2 Inhibitor, Sialic Acid Binding Ig Like Lectin 6 Inhibitor, and Toll Like Receptor 4 Antagonist.
-
What are the key routes of administration in the Contact Dermatitis pipeline drugs market?
The key routes of administration in the Contact Dermatitis pipeline drug market Topical, Cutaneous, Intramuscular, Intravenous, Intravenous Drip, and Nasal. Topical has the maximum number of pipeline products.
-
What are the key molecule types in the Contact Dermatitis pipeline drugs market?
The key molecule types in the Contact Dermatitis pipeline drug market are Small Molecule, Biologic, Monoclonal Antibody, and Live Attenuated Vaccine.
-
What are the major companies in the Contact Dermatitis pipeline drugs market?
In the Contact Dermatitis pipeline drugs market the major companies are Edesa Biotech Inc, Allakos Inc, Aposcience AG, Hapten Sciences Inc, ILiAD Biotechnologies LLC, NextPhase Therapeutics, and Signum Dermalogix Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.